Flunitrazolam (1-methyl-8-nitro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine), a new synthetic depressant substance belonging to the benzodiazepine family, produces anxiolytic and disinhibiting effects. Flunitrazolam is a unique benzodiazepine compound that has a microgram active range. This makes it very potent. Flubromazolam, clonazolam, and other compounds share this trait.
Flunitrazolam was first introduced to the market for research chemicals in 2016. Flunitrazolam first appeared on the research chemicals market in 2016. It was typically found as pressed pellets, along with other novel benzoodiazepines like flunitrazepam or flubromazolam. This compound is completely new and has never been published in scientific literature. It is now available online. It is important to be cautious about information regarding the dosage, effects, or toxicity of this compound. Any speculation regarding its pharmacology is based on the subjective effects it causes and its structural similarity with triazolam,pyrazolam and others benzodiazepines.
Flunitrazolam belongs to the benzodiazepine chemical class. Flunitrazolam’s name refers to the fluorine and bromine substitutions in its core benzodiazepine skeleton. (FLUorine -NITro -AZOLe-AM). Flunitrazolam belongs to the benzodiazepine family because it has a 1,4-diazepine ring that is fused with a substitutedbenzene. This bicyclic structure is also bound to bromine at R7. A fluorine substituted Phenyl ring is also bound to this bicyclic structure at R5.
Flunitrazolam also has a methylated triazole-ring that is fused to and incorporating R1 & R2 of its diazepine rings. Flunitrazolam is part of the triazolobenzodiazepines group that contains this fused triazole rings. It’s identified by the suffix “zolam”.
The benzodiazepines have a wide range of effects. They bind to the benzodiazepine-receptor site and increase the effectiveness and effects of neurotransmitter Gamma aminobutyric Acid (GABA) through their receptors. This site is the most important inhibitory receptor in the brain and modulates flunitrazolam’s sedating or calming effects on the nervous system.
The anticonvulsant effects of benzodiazepines could be due in part or whole to their binding to voltage-dependent sodium channel channels, rather than to benzodiazepine receptors.
Flunitrazolam has been shown to cause sedation and disinhibition in some studies.